Influenza vaccination strategies targeting the hemagglutinin stem region.

Publisher: Blackwell Country of Publication: England NLM ID: 7702118 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-065X (Electronic) Linking ISSN: 01052896 NLM ISO Abbreviation: Immunol Rev Subsets: MEDLINE

Publication: <2002-> : Oxford : Blackwell
Original Publication: Copenhagen, Munksgaard.

Vaccination*/methods; Epitopes/*immunology ; Hemagglutinin Glycoproteins, Influenza Virus/*immunology ; Influenza A virus/*immunology ; Influenza Vaccines/*immunology ; Influenza, Human/*immunology ; Influenza, Human/*prevention & control; Animals ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; B-Lymphocytes/immunology ; B-Lymphocytes/metabolism ; Binding Sites ; Cross Reactions/immunology ; Epitopes/chemistry ; Epitopes/genetics ; Hemagglutinin Glycoproteins, Influenza Virus/chemistry ; Hemagglutinin Glycoproteins, Influenza Virus/genetics ; Humans ; Immunologic Memory ; Influenza A virus/classification ; Protein Binding ; Structure-Activity Relationship ; Vaccinology

Influenza is one of the best examples of highly mutable viruses that are able to escape immune surveillance. Indeed, in response to influenza seasonal infection or vaccination, the majority of the induced antibodies are strain-specific. Current vaccine against the seasonal strains with the strategy of surveillance-prediction-vaccine does not cover an unmet virus strain leading to pandemic. Recently, antibodies targeting conserved epitopes on the hemagglutinin (HA) protein have been identified, albeit rarely, and they often showed broad protection. These antibody discoveries have brought the feasibility to develop a universal vaccine. Most of these antibodies bind the HA stem domain and accumulate in the memory B cell compartment. Broadly reactive stem-biased memory responses were induced by infection with antigenically divergent influenza strains and were able to eradicate these viruses, together indicating the importance of generating memory B cells expressing high-quality anti-stem antibodies. Here, we emphasize recent progress in our understanding of how such memory B cells can be generated and discuss how these advances may be relevant to the quest for a universal influenza vaccine.
(© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Nat Med. 2014 Feb;20(2):143-51. (PMID: 24412922)
J Immunol. 2017 Apr 1;198(7):2819-2833. (PMID: 28250157)
Science. 2015 Sep 18;349(6254):1301-6. (PMID: 26303961)
NPJ Vaccines. 2019 Jan 23;4:4. (PMID: 30701093)
Science. 2016 Mar 4;351(6277):1048-54. (PMID: 26912368)
J Immunol. 2011 Oct 1;187(7):3785-97. (PMID: 21908739)
Sci Transl Med. 2013 Aug 14;5(198):198ra107. (PMID: 23946196)
Vaccine. 1996 Jan;14(1):85-92. (PMID: 8821654)
Curr Opin Immunol. 2017 Apr;45:21-30. (PMID: 28088708)
Cell. 2015 Jun 18;161(7):1505-15. (PMID: 26091035)
Int Immunol. 2020 Jul 28;32(8):499-507. (PMID: 32060507)
Emerg Infect Dis. 2006 Jan;12(1):48-54. (PMID: 16494717)
Sci Transl Med. 2017 Jun 7;9(393):. (PMID: 28592561)
Front Immunol. 2019 Jun 25;10:1457. (PMID: 31316510)
Cell Rep. 2019 Nov 26;29(9):2796-2809.e5. (PMID: 31775046)
J Immunol. 2013 Sep 15;191(6):3186-3191. (PMID: 23940276)
Science. 2012 Sep 14;337(6100):1343-8. (PMID: 22878502)
Science. 2009 Apr 10;324(5924):246-51. (PMID: 19251591)
Vaccine. 2013 Nov 4;31(46):5339-48. (PMID: 24055351)
Immunity. 2013 Oct 17;39(4):758-69. (PMID: 24035365)
Sci Immunol. 2017 Jan 27;2(7):. (PMID: 28783670)
Lancet. 2018 Mar 31;391(10127):1285-1300. (PMID: 29248255)
Nature. 1996 Jun 27;381(6585):751-8. (PMID: 8657279)
J Exp Med. 2019 Aug 5;216(8):1857-1873. (PMID: 31175140)
Immunity. 2017 Oct 17;47(4):599-603. (PMID: 29045889)
J Immunol. 2013 Aug 1;191(3):1260-75. (PMID: 23825311)
Ther Adv Vaccines Immunother. 2019 Nov 7;7:2515135519885547. (PMID: 35174313)
J Clin Microbiol. 1986 Jul;24(1):157-60. (PMID: 3722363)
J Virol. 2013 Jun;87(12):6542-50. (PMID: 23576508)
Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):E2567-75. (PMID: 24821781)
Immunity. 2019 Aug 20;51(2):398-410.e5. (PMID: 31350180)
Science. 2011 Aug 12;333(6044):843-50. (PMID: 21737702)
Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):E3224-33. (PMID: 25053813)
Nat Immunol. 2017 Apr;18(4):456-463. (PMID: 28192417)
Nat Immunol. 2016 Jul;17(7):861-9. (PMID: 27158841)
J Gen Virol. 1996 Jul;77 ( Pt 7):1483-7. (PMID: 8757990)
Sci Immunol. 2016 Jul 29;1(1):aag0851. (PMID: 28783677)
Cell. 2020 Jan 9;180(1):92-106.e11. (PMID: 31866068)
PLoS Pathog. 2014 May 01;10(5):e1004103. (PMID: 24788925)
Nucleic Acids Res. 2019 Jul 2;47(W1):W256-W259. (PMID: 30931475)
J Clin Invest. 1937 Mar;16(2):237-43. (PMID: 16694474)
Sci Rep. 2019 Mar 5;9(1):3492. (PMID: 30837606)
Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13701-6. (PMID: 20615991)
Nat Commun. 2019 Sep 20;10(1):4316. (PMID: 31541110)
Nat Rev Immunol. 2015 Mar;15(3):149-59. (PMID: 25677494)
Cell Host Microbe. 2018 Oct 10;24(4):569-578.e4. (PMID: 30308159)
Science. 2011 Aug 12;333(6044):850-6. (PMID: 21798894)
Sci Transl Med. 2015 Jul 29;7(298):298ra120. (PMID: 26223303)
J Immunol. 2016 Dec 1;197(11):4351-4359. (PMID: 27794001)
J Immunol. 2013 Sep 15;191(6):3179-85. (PMID: 23940273)
mBio. 2016 Jan 19;7(1):e01996-15. (PMID: 26787832)
Nat Immunol. 2018 Apr;19(4):386-396. (PMID: 29556002)
Syst Biol. 2003 Oct;52(5):696-704. (PMID: 14530136)
Nature. 2012 Sep 27;489(7417):566-70. (PMID: 22932267)
Immunity. 2016 Sep 20;45(3):471-482. (PMID: 27653600)
J Clin Invest. 2016 Feb;126(2):605-10. (PMID: 26731473)
J Hyg (Lond). 1972 Dec;70(4):767-77. (PMID: 4509641)
Annu Rev Immunol. 2013;31:705-42. (PMID: 23330954)
Nat Med. 2015 Sep;21(9):1065-70. (PMID: 26301691)
Nat Rev Drug Discov. 2015 Mar;14(3):167-82. (PMID: 25722244)
Cell. 2018 Apr 5;173(2):417-429.e10. (PMID: 29625056)
J Virol. 2013 Jun;87(12):7149-54. (PMID: 23552413)
Trends Immunol. 2011 Nov;32(11):524-31. (PMID: 21940217)
Int Immunol. 2019 Nov 8;31(12):771-779. (PMID: 31231764)
Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):181-6. (PMID: 20018688)
J Virol. 1993 May;67(5):2552-8. (PMID: 7682624)
Sci Rep. 2017 May 31;7(1):2530. (PMID: 28566683)
Nature. 2010 Sep 30;467(7315):591-5. (PMID: 20882016)
Sci Transl Med. 2015 Dec 2;7(316):316ra192. (PMID: 26631631)
Immunity. 2019 Oct 15;51(4):735-749.e8. (PMID: 31563464)
Sci Rep. 2017 Jan 16;7:40312. (PMID: 28091576)
Immunity. 2019 May 21;50(5):1132-1148. (PMID: 31117010)
Annu Rev Immunol. 1994;12:117-39. (PMID: 8011279)
JAMA. 1962 Oct 6;182:11-3. (PMID: 13883724)
Vaccine. 2012 Jun 29;30(31):4655-60. (PMID: 22575166)
J Immunol. 2015 May 15;194(10):4836-45. (PMID: 25870238)
Nat Immunol. 2016 Oct;17(10):1226-34. (PMID: 27525369)
Curr Top Microbiol Immunol. 1989;146:107-16. (PMID: 2659262)
Immunol Rev. 2020 Jul;296(1):132-141. (PMID: 32542739)
Immunity. 2016 Jan 19;44(1):116-130. (PMID: 26795247)
Clin Transl Immunology. 2016 May 20;5(5):e85. (PMID: 27350884)
Nat Commun. 2019 Aug 28;10(1):3883. (PMID: 31462639)

Keywords: HA stem; TFH cell; germinal center B cells; immunodominant; universal

0 (Antibodies, Neutralizing)
0 (Antibodies, Viral)
0 (Epitopes)
0 (Hemagglutinin Glycoproteins, Influenza Virus)
0 (Influenza Vaccines)

Date Created: 20200617 Date Completed: 20210811 Latest Revision: 20220716

20250114

PMC7323124

10.1111/imr.12887

32542739